2024
Jun 26
Dr. Lee has been selected as a finalist in the Business Plan Competition at the TERMIS World Congress 2024.
Jun 25
Bioprinting Laboratories Inc. attended the TERMIS World Congress 2024 and set up a booth to market pillar/perfusion plate products.
Jun 19
The first purchase order received from our customer for pillar/perfusion plate products.
Jun 10
Bioprinting Laboratories Inc. attended the MPS World Summit 2024 and set up a booth to market pillar/perfusion plate products.
Jun 5
Bioprinting Laboratories Inc. has officially launched pillar/perfusion plates and associated accessories for the static and dynamic culture of 3D cells and organoids in the market.
Mar 1
Bioprinting Laboratories Inc. established mass production protocols for pillar/perfusion plates and conducted beta tests with potential customers to ensure quality control.
2023
Aug 1

Bioprinting Laboratories Inc. awarded $285,000 NIH/NIEHS SBIR Phase I grant for developing genetically engineered human liver organoids to assess hepatotoxicity among poor and ultrafast metabolizers.

Bioprinting Laboratories Inc. has been relocated to Dallas, Texas.

Jun 1

Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research.

Apr 12

Dr. Lee received “Third Place Award” in Business Plan Competition at TERMIS-AM 2023 Conference.

Feb 14

Bioprinting Laboratories Inc. received $1 million angel investment for commercialization of pillar/perfusion plates for human organoid culture and analysis.

2022
Sep 23

Dr. Lee is selected as a Cohort of BioNTX Tech Transfer Office Showcase and Pitch Competition at 2022 iC3 Life Science Summit.

Apr 12

Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research.

2021
Sep 1

Bioprinting Laboratories Inc. awarded $50,000 grant from Colgate-Palmolive for antimicrobial research.

Aug 16
Bioprinting Laboratories Inc. has been relocated to Denton, Texas.
2020
Aug 6

Dr. Lee and his research collaborators at Cincinnati Children’s Hospital Medical Center and University of Illinois at Chicago awarded $5.35 million NIH/NIDDK UH3 grant for modeling type II diabetes on pillar/perfusion plate platforms.

Jul 16

Bioprinting Laboratories Inc. awarded $838,000 NIH/NCATS SBIR Phase II grant for commercializing pillar/perfusion plate platforms for robust organoid culture and analysis.

2019
May 1
Dr. Lee awarded $150,000 TVSF Phase II grant for his startup company, Bioprinting Laboratories Inc.
Feb 28
Dr. Lee awarded $80,000 grant from Colgate-Palmolive for antimicrobial research.
2018
Oct 16
Dr. Lee and his team received $1.69 million grant to enhance disease modeling.
Feb 28

Dr. Lee awarded $100,000 TeCK Fund grant for commercialization of microarray 3D bioprinting technology.

2017
Nov 11

Dr. Lee established Bioprinting Laboratories Inc. to commercialize “microarray 3D bioprinting” technology.

Feb 28

Dr. Lee's team is selected as 2017 Cohort of I-Corps@Ohio program. In this program, Dr. Lee and his team members will develop business strategy and market analysis for commercializing a 384-pillar plate with sidewalls for miniaturized human tissue regeneration.

Another Unique Feature... Convenient Culture Medium Change

Did you know... Use of the perfusion plate without pumps and tubes makes it easy to change growth media for long-term organoid culture as well as drug-organoid and organoid-organoid interactions. Another unique technological feature brought to you by the innovation of Bioprinting Laboratories Inc.